Back to News
Market Impact: 0.52
Celldex's Barzolvolimab Meets Phase 3 Goals In Chronic Hives Studies; Stock Down
Source: Nasdaq
Healthcare & Biotech
Celldex reported positive topline results from two Phase 3 trials of barzolvolimab in chronic spontaneous urticaria (chronic hives). The treatment met its primary endpoint and all key secondary endpoints, materially improving the clinical and regulatory outlook for the program.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.82
Ticker Sentiment
CLDX0.90
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Jefferies raises Inovio stock price target on regulatory win
- Humana lifts annual profit forecast as medical costs ease
- Truist raises Vericel stock price target on MACI growth momentum